Abstract | BACKGROUNDS: Recently, the term biomarker has become, especially in connection with the term clinical proteomics, one of the most frequent terms in the field of biomedical research. The aim of this work was to select an appropriate pre-fractionation method of blood plasma prior to a subsequent proteomic analysis of low-abundant fraction of proteins by two dimensional gel electrophoresis (2-DE) and mass spectrometry to improve the resolution of 2-DE maps and protein identification. MATERIALS AND METHODS: First, we compared two prefractionation methods (MARS versus ProteoMiner) preceding 2-DE analysis using 10 blood plasma samples. Based on the results of the comparative experiments, low-abundant plasma protein fractions from 18 multiple myeloma patients treated with bortezomib were analyzed. Patients were divided into two groups: a group resistant to chemotherapy (9 patients-- disease progression, stable disease) and a group with positive clinical response (9 patients--complete and partial remission). RESULTS AND CONCLUSION:
|
Authors | J Cumová, L Jedličková, D Potěšil, O Sedo, K Stejskal, A Potáčová, Z Zdráhal, R Hájek |
Journal | Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
(Klin Onkol)
Vol. 25
Issue 1
Pg. 17-25
( 2012)
ISSN: 0862-495X [Print] Czech Republic |
Vernacular Title | Srovnávací proteomická analýza krevní plazmy pacientů s mnohočetným myelomem léčených režimy s bortezomibem. |
PMID | 22348216
(Publication Type: Comparative Study, English Abstract, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Biomarkers
- Blood Proteins
- Boronic Acids
- Pyrazines
- Bortezomib
|
Topics |
- Aged
- Antineoplastic Agents
(therapeutic use)
- Biomarkers
(blood)
- Blood Proteins
(analysis)
- Boronic Acids
(therapeutic use)
- Bortezomib
- Electrophoresis, Gel, Two-Dimensional
- Female
- Humans
- Male
- Mass Spectrometry
- Multiple Myeloma
(blood, drug therapy)
- Proteomics
- Pyrazines
(therapeutic use)
|